Overview

Sex-Specific Cerebrovascular Dysfunction in Metabolic Syndrome-Role of COX

Status:
NOT_YET_RECRUITING
Trial end date:
2031-07-01
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that Metabolic Syndrome (MetSyn) decreases cerebral blood flow (CBF) more in females than males due in part to the sex-specific loss of COX vasodilation. Male and female participants will be enrolled in two groups: Health Controls versus participants with MetSyn.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
National Institutes of Health (NIH)
Treatments:
Indomethacin
Lactose
Magnetic Resonance Imaging